909 related articles for article (PubMed ID: 16971520)
1. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
[TBL] [Abstract][Full Text] [Related]
2. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
Barnum CJ; Chen X; Chung J; Chang J; Williams M; Grigoryan N; Tesi RJ; Tansey MG
J Parkinsons Dis; 2014; 4(3):349-60. PubMed ID: 25061061
[TBL] [Abstract][Full Text] [Related]
3. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
4. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
5. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
7. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.
McCoy MK; Ruhn KA; Martinez TN; McAlpine FE; Blesch A; Tansey MG
Mol Ther; 2008 Sep; 16(9):1572-9. PubMed ID: 18628756
[TBL] [Abstract][Full Text] [Related]
8. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.
Harms AS; Barnum CJ; Ruhn KA; Varghese S; Treviño I; Blesch A; Tansey MG
Mol Ther; 2011 Jan; 19(1):46-52. PubMed ID: 20959812
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
11. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Liang ZQ; Li YL; Zhao XL; Han R; Wang XX; Wang Y; Chase TN; Bennett MC; Qin ZH
Brain Res; 2007 May; 1145():190-203. PubMed ID: 17368433
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
13. Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation.
Chen HQ; Jin ZY; Li GH
Neurosci Lett; 2007 May; 417(2):112-7. PubMed ID: 17399896
[TBL] [Abstract][Full Text] [Related]
14. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats.
Cicchetti F; Lapointe N; Roberge-Tremblay A; Saint-Pierre M; Jimenez L; Ficke BW; Gross RE
Neurobiol Dis; 2005 Nov; 20(2):360-71. PubMed ID: 16242641
[TBL] [Abstract][Full Text] [Related]
15. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Crocker SJ; Wigle N; Liston P; Thompson CS; Lee CJ; Xu D; Roy S; Nicholson DW; Park DS; MacKenzie A; Korneluk RG; Robertson GS
Eur J Neurosci; 2001 Jul; 14(2):391-400. PubMed ID: 11553289
[TBL] [Abstract][Full Text] [Related]
16. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain.
Ling ZD; Chang Q; Lipton JW; Tong CW; Landers TM; Carvey PM
Neuroscience; 2004; 124(3):619-28. PubMed ID: 14980732
[TBL] [Abstract][Full Text] [Related]
17. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
18. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
19. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
